Article
Biochemistry & Molecular Biology
Mingxin Bai, Liling Xu, Huaqun Zhu, Jimeng Xue, Tian Liu, Feng Sun, Haihong Yao, Zhen Zhao, Ziye Wang, Ranran Yao, Fanlei Hu, Yin Su
Summary: This study revealed a decrease in GrB-producing Bregs in SLE patients, which correlated with clinical and immunological features. Furthermore, these cells exhibited impaired function under SLE conditions. The negative correlation between GrB-producing Bregs and CD4(+) T cells observed in healthy individuals disappeared in SLE patients.
MOLECULAR IMMUNOLOGY
(2021)
Article
Immunology
Nasren Eiza, Adi D. Sabag, Ofra Kessler, Gera Neufeld, Zahava Vadasz
Summary: CD72 serves as a ligand and signal transducing receptor for sema3A, independent of neuropilin-1 (NRP-1), in B cells. Sema3A binding to CD72 on B cells inhibits the phosphorylation of STAT-4 and HDAC-1 and induces the phosphorylation of p38-MAPK and PKC-theta. The sema3A-CD72 axis is a crucial regulatory pathway in the pathogenesis of SLE.
JOURNAL OF AUTOIMMUNITY
(2023)
Article
Immunology
Daniele Mauro, Sotiria Manou-Stathopoulou, Felice Rivellese, Elisabetta Sciacca, Katriona Goldmann, Victoria Tsang, Isabelle Lucey-Clayton, Sara Pagani, Farah Alam, Debasish Pyne, Ravindra Rajakariar, Patrick A. Gordon, James Whiteford, Michele Bombardieri, Costantino Pitzalis, Myles J. Lewis
Summary: Study finds that UBE2L3 plays a critical role in TLR7-mediated NF-??B activation in Systemic Lupus Erythematosus (SLE). Inhibition of UBE2L3 by Dimethyl Fumarate (DMF) can effectively suppress TLR7-induced NF-??B activation, B cell differentiation, and autoantibody production in SLE. This suggests that UBE2L3 inhibition could be a potential therapeutic strategy for SLE by repurposing DMF.
JOURNAL OF AUTOIMMUNITY
(2023)
Review
Oncology
Kaichi Kaneko, Hao Chen, Matthew Kaufman, Isaak Sverdlov, Emily M. Stein, Kyung-Hyun Park-Min
Summary: Osteonecrosis is a complex and devastating complication of systemic lupus erythematosus, with variable prevalence in SLE patients. The use of high-dose glucocorticoid therapy is strongly associated with the development of osteonecrosis in SLE patients, although the exact pathophysiology and risk factors for osteonecrosis in this population are not fully understood.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Immunology
Izumi Kurata, Natsuko Mikami, Ayako Ohyama, Atsumu Osada, Yuya Kondo, Hiroto Tsuboi, Takayuki Sumida, Isao Matsumoto
Summary: The study found that SLE-TFR cells have functional defects in suppressing TFH cells, leading to decreased ability to inhibit them, and their PD-1 expression is correlated with disease activity and antibody levels. However, low-dose IL-2 therapy may be helpful in restoring this inhibitory function.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Fanny Urbain, Maharajah Ponnaiah, Farid Ichou, Marie Lhomme, Clement Materne, Sophie Galier, Julien Haroche, Eric Frisdal, Alexis Mathian, Herve Durand, Micheline Pha, Miguel Hie, Anatol Kontush, Philippe Cluzel, Philippe Lesnik, Zahir Amoura, Maryse Guerin, Fleur Cohen Aubart, Wilfried Le Goff
Summary: This study uncovers the contribution of disturbed metabolism to the presence of coronary artery calcium and the associated risk of coronary heart disease in patients with systemic lupus erythematosus (SLE). Identification of novel lipid and metabolite biomarkers may help stratifying patients for reducing cardiovascular disease morbidity and mortality in SLE.
Review
Immunology
Yi-Giien Tsai, Pei-Fen Liao, Kai-Hung Hsiao, Hung-Ming Wu, Ching-Yuang Lin, Kuender D. Yang
Summary: Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease. Immune regulatory cells, particularly Treg subsets, and low-dose IL-2 therapy play important roles in the pathogenesis and treatment of SLE.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Swayanka Biswas, Katja Bieber, Rudolf Armin Manz
Summary: IL-10 is a cytokine that has pleiotropic effects on immune cells, including both suppressive and activating functions. It plays a dual role in Systemic lupus Erythematosus (SLE), inhibiting pro-inflammatory effector functions while also promoting extrafollicular antibody response. IL-10 is produced by B cells, myeloid cells, and certain T cell subsets, and it drives B cell responses, proliferation, class switching, and plasma cell formation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Gan Zhang, Fan Yang, Juan Li, Shan Chen, Yuhang Kong, Chunfen Mo, Xiao Leng, Yang Liu, Ying Xu, Yantang Wang
Summary: A study found that quinazoline derivatives can inhibit the activation of B cells and reduce the severity of systemic lupus erythematosus (SLE). Treatment with quinazoline derivatives decreased the frequency of activated B cells and plasma cells, improving the disease severity. This research suggests that quinazoline derivatives may be an excellent candidate for the treatment of SLE and other autoimmune diseases.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Urology & Nephrology
Na Kang, Xiaohang Liu, Xujie You, Wenbo Sun, Kabeer Haneef, Xiaolin Sun, Wanli Liu
Summary: Aberrant B-cell activation is closely linked to the pathogenesis of SLE, with dysregulations of B-cell receptor (BCR), toll-like receptor (TLR), and B-cell activating factor receptor (BAFF-R) pathways being common factors. Targeting these aberrant signaling pathways has shown promise in alleviating clinical symptoms of SLE, emphasizing the importance of identifying new drug targets for future therapeutic strategies.
Article
Pharmacology & Pharmacy
Yi Zhang, FengQi Zhang, YiNi Gao, MeiJiao Wang, Yan Gao, HaiChang Li, Jing Sun, ChengPing Wen, ZhiJun Xie
Summary: Through experimental evidence, it has been found that triptolide (TP) exerts therapeutic effects on SLE by regulating miR-146a expression, inhibiting the TLR7/NF-kappa B signaling pathway, and affecting B cell activation.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Maria Garcia-Gonzalez, Fuensanta Gomez-Bernal, Juan C. Quevedo-Abeledo, Yolanda Fernandez-Cladera, Agustin F. Gonzalez-Rivero, Raquel Lopez-Mejias, Federico Diaz-Gonzalez, Miguel a. Gonzalez-Gay, Ivan Ferraz-Amaro
Summary: This study analyzed the relationship between the complement (C) system and cholesterol efflux capacity (CEC) in patients with systemic lupus erythematosus (SLE). The study found that there is an interconnected relationship between the C system and CEC in patients with SLE.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Rheumatology
Jimeng Xue, Liling Xu, Hua Zhong, Mingxin Bai, Xin Li, Ranran Yao, Ziye Wang, Zhen Zhao, Hongchao Li, Huaqun Zhu, Fanlei Hu, Yin Su
Summary: Recently, a new subtype of GrB-producing Breg cells has been found to be associated with autoimmune disease. This study investigated the role of GrB-producing Breg cells in lupus mice and showed their impact on T cell homeostasis. The findings highlight GrB-producing Breg cells as a potential therapeutic target for SLE.
LUPUS SCIENCE & MEDICINE
(2023)
Review
Immunology
Paul Curtiss, Amanda M. Walker, Benjamin F. Chong
Summary: This study reviewed patient cohorts and populations to investigate the progression of cutaneous lupus to systemic lupus. The study found variations in the progression rates between adult and pediatric groups, which were attributed to differences in patient populations, study design, diagnostic criteria, and follow-up time. Risk factors associated with the development of systemic lupus included positive anti-nuclear antibodies, hematologic abnormalities, and a higher number of lupus classification criteria at baseline.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Masahiro Ayano, Takahiko Horiuchi
Summary: Systemic lupus erythematosus (SLE) is a disease where complement is crucial in its pathogenesis. Complement levels in blood and histological tests are used for SLE management, and the evaluation of complement status is useful for diagnosis, disease activity assessment, treatment response prediction, and prognosis. Novel complement biomarkers are more sensitive than traditional markers and have wider application. This review summarizes the utility of complement testing in SLE management over the last decade.